All In MedTech

FDA Clearance Tracker · P240036-S004

OmniaSecure™ MRI SureScan™ Lead Model 3930M

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplementBreakthrough

Decided

Mar 9, 2026

Approved

Time to decision

90 days

Received Dec 9, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P240036-S004
Device name
OmniaSecure™ MRI SureScan™ Lead Model 3930M
Applicant location
Mounds View, MN
Received
Dec 9, 2025
Decided
Mar 9, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P240036

Device type

Device class
Class III

Every decision under product code NVY

FDA's approval statement

As written in FDA's record.

Approval for updated indications and labeling changes with Left Bundle Branch Area Pacing (LBBAP) application for the OmniaSecure™ MRI SureScan™ 3930M lead

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.